Storia in 10 fonti

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo3 mesi fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

originale

Timeline cronologica

sabato 30 maggio 2026·morningstar.com
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
domenica 31 maggio 2026·biopharmadive.com
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Confronto fonti

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Timeline cronologica

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso lung cancer drug trial raises hopes in US$20b market

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

New drug a ‘promising step forward’ for hard-to-treat lung cancer

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy…

Newly developed drug helps extend the lives of lung cancer patients in trial

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial

A turning point for pancreatic cancer patients